1
|
Alkerata A, Al-Janabi MH, Ahmad YI, Jbeili SS, Ahmad IY. Primary breast lymphoma: A rare case report. Int J Surg Case Rep 2024; 122:110120. [PMID: 39098174 PMCID: PMC11359985 DOI: 10.1016/j.ijscr.2024.110120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2024] [Revised: 07/26/2024] [Accepted: 08/01/2024] [Indexed: 08/06/2024] Open
Abstract
INTRODUCTION AND IMPORTANCE Primary breast lymphoma (PBL) is an extremely rare neoplasm, accounting for less than 1 % of breast malignancies and less than 2 % of extranodal non-Hodgkin lymphomas (NHLs). CASE PRESENTATION This case report discusses a 60-year-old female patient presenting with a primary breast lymphoma, specifically diffuse large B-cell lymphoma. The patient had no personal history of breast cancer but exhibited a painless, palpable mass in the left breast with axillary lymphadenopathy. CLINICAL DISCUSSION Diagnostic challenges in distinguishing PBL from primary breast carcinoma are addressed, emphasizing the importance of considering PBL in cases of rapidly enlarging breast masses. Radiological examinations, including mammography and ultrasound, play a crucial role in diagnosis, and excisional biopsy with immunohistochemical staining is essential for accurate histopathological subcategorization. CONCLUSION The presented case underscores the rarity of PBL in the Middle East and highlights the diagnostic and classification challenges, emphasizing the central role of accurate techniques in guiding treatment decisions.
Collapse
Affiliation(s)
- Ali Alkerata
- AL Andalus Private University for Medical Sciences, Faculty of Medicine, Syria.
| | | | | | - Sohair Salim Jbeili
- Department of General Surgery, Tishreen University Hospital, Lattakia, Syria
| | - Issa Y Ahmad
- Tishreen University and AL Andalus Private University for Medical Sciences, Faculty of Medicine, Department of Pathology, Tishreen University Hospital, Syria.
| |
Collapse
|
2
|
Santiago-Sanabria L, Garza-Arrieta J, Porras-Ibarra GD, Malfavón-Farias M. Linfoma no Hodgkin de células B primario de mama. Reporte de caso y revisión de la literatura. REVISTA COLOMBIANA DE OBSTETRICIA Y GINECOLOGIA 2023; 74:53-67. [PMID: 37093942 PMCID: PMC10174716 DOI: 10.18597/rcog.3844] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/28/2022] [Accepted: 01/24/2023] [Indexed: 04/25/2023]
Abstract
OBJETIVOS reportar un caso de linfoma no Hodgkin de células B primario de mama (LPM) y realizar una revisión de la literatura de su diagnóstico y tratamiento. Materiales y métodos: se reporta el caso de una paciente de 80 años que acudió a una institución privada de referencia en México por un LPM. Además, se diagnosticó un melanoma primario de hígado, mediante biopsia dirigida y estudio de patología. La paciente recibió tratamiento con R-CHOP (rituximab, ciclofosfamida, doxorrubicina, vincristina y prednisona), cuadrantectomía, resección de cadenas ganglionares y radioterapia. La paciente presenta adecuada respuesta del LPM, sin embargo, el segundo tumor primario progresa llevando a la paciente a cuidados paliativos. Se realizó una búsqueda bibliográfica en Medline vía PubMed, LILACS y Google Scholar. Se incluyeron estudios de cohortes, reportes y series de casos en pacientes con LPM que abordaran el diagnóstico, tratamiento y pronóstico de esta patología, publicados en inglés y español entre los años 2000 a 2022. RESULTADOS se identificaron 23 títulos, de los cuales 17 cumplieron con los criterios de inclusión, estos fueron reportes de caso y series de caso. La mayoría de las pacientes recibió un esquema quimioterapéutico R-CHOP, el cual se complementó con radioterapia. Cerca del 80 % presentó remisión completa. El sitio más frecuente de recaída fue el sistema nervioso central. La sobrevida a 5 años fue del 83,6 % en los estudios incluidos. CONCLUSIONES en la actualidad, el esquema CHOP -con o sin rituximab- es el más empleado y el único que ha mostrado tener un impacto positivo en la supervivencia, este suele acompañarse de radioterapia. Se requieren más estudios clínicos aleatorizados para establecer de manera más clara la efectividad y seguridad de estos tratamientos.
Collapse
|
3
|
Abstract
Primary breast lymphoma (PBL) is an uncommon type of breast malignancy. Its clinical presentation and radiographic findings are non-specific and overlap with breast carcinoma. The treatment of PBL differs significantly from breast carcinomas. Here we present a middle-aged woman who presented with an enlarging palpable right breast mass. Mammogram showed breast imaging-reporting and data system 4 findings. Breast mass biopsy pathology confirmed diffuse large B cell lymphoma. Although uncommon, clinicians should be cognisant of the possibility of PBL when patients present with a breast mass. Accurate diagnosis is essential to avoid unnecessary mastectomies.
Collapse
Affiliation(s)
- Mengni Guo
- Internal Medicine Residency, AdventHealth Orlando, Orlando, Florida, USA
| | - Jieying Liu
- Internal Medicine Residency, AdventHealth Orlando, Orlando, Florida, USA
| | - Richard Gilmore
- Breast Surgical Oncology, West Cancer Center, Memphis, Tennessee, USA
| | - Gang Gary Tian
- Medical Oncology/Hematology, West Cancer Center, Memphis, Tennessee, USA
| |
Collapse
|
4
|
Hammood ZD, Salih AM, Latif S, Abdullah HO, Ali RK, Kakamad FH. Primary diffuse B-cell non-Hodgkin's breast lymphoma; A case report with a brief literature review. Ann Med Surg (Lond) 2022; 75:103310. [PMID: 35198180 PMCID: PMC8844393 DOI: 10.1016/j.amsu.2022.103310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2021] [Revised: 01/14/2022] [Accepted: 01/23/2022] [Indexed: 11/29/2022] Open
Affiliation(s)
- Zuhair D. Hammood
- Smart Health Tower, Madam Mitterrand Street, Sulaimani, Kurdistan, Iraq
| | - Abdulwahid M. Salih
- Smart Health Tower, Madam Mitterrand Street, Sulaimani, Kurdistan, Iraq
- College of Medicine, University of Sulaimani, Madam Mitterrand Street, Sulaimani, Kurdistan, Iraq
| | - Shaban Latif
- Smart Health Tower, Madam Mitterrand Street, Sulaimani, Kurdistan, Iraq
| | - Hiwa O. Abdullah
- Smart Health Tower, Madam Mitterrand Street, Sulaimani, Kurdistan, Iraq
- Kscien Organization, Hamdi Str, Azadi Mall, Sulaimani, Kurdistan, Iraq
| | - Razhan K. Ali
- Department of Cardiothoracic Surgery, Shar Hospital, Sulaimani, Iraq
| | - Fahmi H. Kakamad
- Smart Health Tower, Madam Mitterrand Street, Sulaimani, Kurdistan, Iraq
- College of Medicine, University of Sulaimani, Madam Mitterrand Street, Sulaimani, Kurdistan, Iraq
- Kscien Organization, Hamdi Str, Azadi Mall, Sulaimani, Kurdistan, Iraq
- Corresponding author. Doctor City, Building 11, Apartment 50, Sulaimani, Iraq.
| |
Collapse
|
5
|
Incidentally detected Non-Hodgkin's lymphoma of the breast. A case report with review of literature. Radiol Case Rep 2020; 16:205-209. [PMID: 33294090 PMCID: PMC7691161 DOI: 10.1016/j.radcr.2020.11.009] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2020] [Revised: 10/31/2020] [Accepted: 11/02/2020] [Indexed: 11/23/2022] Open
Abstract
We report a case of primary breast lymphoma which was incidentally detected in a 71 year-old-female while investigating for pulmonary embolism with Computed tomography angiograph (CTA) of the chest. Primary breast lymphoma has no specific imaging features however may have better prognosis than breast carcinoma and management is non-surgical.
Collapse
|
6
|
Zhang T, Zhao H, Cui Z, Xu H, Liu X, Wu Y, Li Y, Sun S, Wang P, Wang Y, Shi X. A multicentre retrospective study of primary breast diffuse large B-cell and high-grade B-cell lymphoma treatment strategies and survival. ACTA ACUST UNITED AC 2020; 25:203-210. [PMID: 32476626 DOI: 10.1080/16078454.2020.1769419] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Objectives: Primary breast diffuse large B-cell lymphoma (PB-DLBCL) and primary breast high-grade B-cell lymphoma (PB-HGBCL) are rare extranodal aggressive B-cell lymphomas with distinct characteristics. Reliable data regarding appropriate treatment of these specific entities are lacking due to their rarity.Methods: We reviewed 36 patients diagnosed at four Chinese medical centres between January 2008 and December 2018. Data regarding clinicopathological features, therapeutic evaluation and central nervous system (CNS) relapse were collected, and overall survival (OS) and progression-free survival (PFS) were calculated.Results: Among the 36 patients, there were 29 PB-DLBCL patients and 7 PB-HGBCL patients. The 5-year OS for PB-DLBCL and PB-HGBCL was 75.9% and 28.6%, respectively. The 5-year PFS for PB-DLBCL and PB-HGBCL was 69.0% and 14.3%, respectively. The R-DAEPOCH regimen was significantly more effective in PB-DLBCL patients than the R-CHOP regimen (5-year OS: 78.9% vs 62.5%, P=0.024; 5-year PFS: 73.7% vs 50.0%, P=0.037) but resulted in more severe myelosuppression (P=0.025). The rate of CNS relapse was 17.2% in PB-DLBCL patients and 28.6% in PB-HGBCL patients; the difference was not significant (P=0.602). The R-DAEPOCH regimen did not predominantly reduce CNS recurrence as expected (P=0.616). The Cox proportional hazards model revealed that risk stratification and triple expression were independent prognostic factors.Conclusion: Current treatments, including more intensive chemotherapy regimens, achieve good control of the disease. Novel drugs combined with cellular immunotherapy initially show promising therapeutic effects, and more clinical trials are required to confirm these effects further.
Collapse
Affiliation(s)
- Tingting Zhang
- Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China
| | - Hongguo Zhao
- Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China
| | - Zhongguang Cui
- Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China
| | - Haicang Xu
- Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China
| | - Xiaodan Liu
- Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China
| | - Ying Wu
- Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China
| | - Ying Li
- Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China
| | - Shuxiang Sun
- Department of Hematology, Yuhuangding Hospital of Yantai, Affiliated Hospital of Qingdao Medical University, Yantai, People's Republic of China
| | - Peijun Wang
- Department of Hematology, Qingdao Central Hospital, Qingdao, People's Republic of China
| | - Yanli Wang
- Department of Hematology, Linyi Central Hospital, Linyi, People's Republic of China
| | - Xue Shi
- Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China
| |
Collapse
|
7
|
Yoneyama K, Nakagawa M, Hara A. Primary lymphoma of the breast: A case report and review of the literature. Radiol Case Rep 2020; 16:55-61. [PMID: 33193929 PMCID: PMC7644561 DOI: 10.1016/j.radcr.2020.10.039] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2020] [Revised: 10/19/2020] [Accepted: 10/23/2020] [Indexed: 11/29/2022] Open
Abstract
Primary lymphoma of the breast is a rare disease, accounting for about 0.5% of all primary breast tumors. Often found as a solitary indolent mass, it is difficult to distinguish from breast cancer on imaging and is often diagnosed for the first time based on histological findings. Diffuse large B-cell lymphoma is the most common histological subtype. A 48-year-old woman visited our hospital because of a painless mass in the left breast. Breast cancer was suspected based on the imaging findings. A core needle biopsy was performed, and the invasive ductal carcinoma was diagnosed. Partial mastectomy and sentinel lymph node biopsy were performed. The resected specimen was finally diagnosed as diffuse large B-cell lymphoma based on immunohistochemical staining. The patient was treated with R-CHOP and intrathecal injection of methotrexate. The patient remains alive without recurrence 4 years later. Awareness of primary breast lymphoma is essential for accurate and timely diagnosis and avoidance of unnecessary surgery.
Collapse
Affiliation(s)
- Kimiyasu Yoneyama
- Department of Breast Surgery, Hiratsuka City Hospital, 1-19-1 Minamihara, Hiratsuka-shi, Kanagawa 254-0065, Japan
| | - Motohito Nakagawa
- Department of Breast Surgery, Hiratsuka City Hospital, 1-19-1 Minamihara, Hiratsuka-shi, Kanagawa 254-0065, Japan
| | - Asuka Hara
- Department of Breast Surgery, Hiratsuka City Hospital, 1-19-1 Minamihara, Hiratsuka-shi, Kanagawa 254-0065, Japan
| |
Collapse
|